Hydroxychloroquine Associated With Lower COVID-19 Mortality: October 2023 Study
COVID patients who were treated with hydroxychloroquine were less likely to die than those who weren't, according to a new study.Researchers examined records from 30,423 patients with COVID-19 who were treated at another institution in Marseille, IHU Méditerranée Infection. They included all adults who tested positive for COVID-19 and were treated in the hospital as an inpatient or an outpatient between March 2, 2020, and Dec. 31, 2021.
The study set ended up with 30,202 patients because treatment information wasn't available for the 221 others.
Most of the patients received off-label prescriptions of hydroxychloroquine and azithromycin (AZ), a common antibiotic. Of the set, 23,172 patients received the drug combination. The other 7,030 did not.
Among those who received the drugs, 191, or 0.8 percent, died. Among those who did not, 344, or 4.8 percent, died.
Those who received HCQ and AZ were more likely to survive regardless of whether they were inpatients or outpatients.
Editor's Note: This study is just one of many that have demonstrated the effectiveness of hydroxychloroquine in reducing COVID-19 mortality (Table below). Among these studies, a significant distinction emerges between initiating treatment early versus late. Late treatment is less likely to be effective when compared to early intervention. However, initiating treatment early presents its own set of challenges, as it may take several days to undergo testing, obtain a prescription, and have it filled. If you are considering stockpiling hydroxychloroquine, it is advisable to consult with a medical doctor online beforehand.